Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after ‘CLAG-M’ vs. ‘MEC’

•We compared CLAG-M and MEC in relapsed and refractory AML.•Response rates were 61 % for CLAG-M and 56 % for MEC.•No significant differences in overall survival were seen between the 2 regimens.•Trends towards improved survival in those treated with MEC then ASCT were noted.•Superior survival may occur in patients with late relapse treated with MEC then ASCT.